使用商业制剂在连续性静脉-静脉血液滤过中进行局部枸橼酸盐抗凝。
Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations.
作者信息
Munjal Sandeep, Ejaz A Ahsan
机构信息
Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, Florida 32610-0224, USA.
出版信息
Nephrology (Carlton). 2006 Oct;11(5):405-9. doi: 10.1111/j.1440-1797.2006.00653.x.
AIM
The aim of the present study was to test the feasibility of using commercial preparations of replacement and citrate anticoagulation solution in continuous venovenous haemofiltration (CVVH) in a safe, efficient and simple manner.
METHODS
Retrospective review of the database of a large continuous renal replacement therapy programme that uses a standardized prescription of high ultrafiltrate CVVH with commercial solutions for replacement fluid and regional citrate anticoagulation was performed.
RESULTS
Records of 28 patients who underwent 91 CVVH sessions were analysed. Median circuit survival time was 37 (59.5-15.5) h and the 48 h survival probability was 40%. Bleeding or metabolic complications were not noted, and the procedure was simple to administer.
CONCLUSION
Continuous venovenous haemofiltration using commercial preparations of replacement fluid and citrate anticoagulation can be safe, efficient and simple.
目的
本研究旨在测试以安全、高效且简单的方式在连续性静脉-静脉血液滤过（CVVH）中使用商品化置换液和枸橼酸盐抗凝溶液的可行性。
方法
对一个大型连续性肾脏替代治疗项目的数据库进行回顾性分析，该项目采用标准化的高超滤量CVVH处方，使用商品化溶液作为置换液并进行局部枸橼酸盐抗凝。
结果
分析了28例患者接受91次CVVH治疗的记录。中位体外循环存活时间为37（59.5 - 15.5）小时，48小时存活概率为40%。未观察到出血或代谢并发症，且该操作易于实施。
结论
使用商品化置换液和枸橼酸盐抗凝进行连续性静脉-静脉血液滤过可以是安全、高效且简单的。
Zotero 插件